Related Experiment Videos
Implantable defibrillators and/or amiodarone: alternatives or complementary therapies
International Journal of Clinical Practice
|January 23, 1999
Summary
For patients with an implanted cardioverter defibrillator (ICD), antiarrhythmic drugs are sometimes needed. Amiodarone is a safe first choice, especially for those with poor heart function and frequent ventricular arrhythmias, but requires careful monitoring.
Area of Science:
- Cardiology
- Electrophysiology
- Pharmacology
Background:
- Implanted cardioverter defibrillators (ICDs) are increasingly used for arrhythmia management.
- Many patients with ICDs also receive antiarrhythmic drug therapy.
- Optimal antiarrhythmic therapy selection is crucial for patients with ICDs.
Purpose of the Study:
- To review the interactions between antiarrhythmic therapies and ICDs.
- To guide the selection of appropriate antiarrhythmic drugs for ICD patients.
- To highlight the importance of monitoring for optimized patient outcomes.
Main Methods:
- Literature review of studies on ICDs and antiarrhythmic drug interactions.
- Analysis of safety and efficacy data for antiarrhythmic drugs in ICD patients.
- Focus on amiodarone as a first-line option for specific patient groups.
Main Results:
- Antiarrhythmic therapy is not always required for ICD patients.
- Amiodarone is a safe and effective first choice for patients with poor left ventricular (LV) function.
- Amiodarone is particularly beneficial for patients with frequent ventricular arrhythmias.
- Close monitoring is essential to manage interactions between ICDs and antiarrhythmic drugs.
Conclusions:
- Antiarrhythmic drug therapy should be individualized for ICD patients.
- Amiodarone is a recommended initial therapy for selected ICD patients, especially those with LV dysfunction and high-burden ventricular arrhythmias.
- Careful management of drug-device interactions is critical for maximizing patient benefit and safety.